⚠️🇪🇺#инфляция #европа #sentiment
Европа - долгосрочные инфляционные ожидания = макс с 2018г
LONG-TERM EURO ZONE INFLATION EXPECTATIONS -1.65% - HIGHEST SINCE LATE 2018
Европа - долгосрочные инфляционные ожидания = макс с 2018г
LONG-TERM EURO ZONE INFLATION EXPECTATIONS -1.65% - HIGHEST SINCE LATE 2018
🇩🇪#Wintershall
Wintershall Dea изменила свою юридическую форму с общества с ООО на АО под названием Wintershall Dea AG - Прайм
Wintershall Dea изменила свою юридическую форму с общества с ООО на АО под названием Wintershall Dea AG - Прайм
⚡️🇺🇸#GE #отчетность
General Electric Q221 Earnings:
Revenue: USD18.3B (est USD18.09B)
Adj EPS: USD0.05 (est USD0.035)
Positive Trajectory In 2021, Though Still Challenged By Aviation
Sees FY Industrial FCF: USD3.5B To USD5.0B (saw: USD2.5B To USD4.5B)
General Electric Q221 Earnings:
Revenue: USD18.3B (est USD18.09B)
Adj EPS: USD0.05 (est USD0.035)
Positive Trajectory In 2021, Though Still Challenged By Aviation
Sees FY Industrial FCF: USD3.5B To USD5.0B (saw: USD2.5B To USD4.5B)
⚡️💥🇺🇸#MRK
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
⚡️🇺🇸#MMM #отчетность
3M Q221 Earnings:
Net Sales: USD8.9B (est USD8.57B)
Adj EPS: USD2.59 (est USD2.27)
Sees FY EPS: USD9.70-USD10.10 (saw: USD9.20 To USD9.70, est: USD9.82)
Sees FY Sales: +7 To +10% (saw: +5 To +8%)
3M Q221 Earnings:
Net Sales: USD8.9B (est USD8.57B)
Adj EPS: USD2.59 (est USD2.27)
Sees FY EPS: USD9.70-USD10.10 (saw: USD9.20 To USD9.70, est: USD9.82)
Sees FY Sales: +7 To +10% (saw: +5 To +8%)
⚡️🇺🇸#BSX #отчетность
Boston Scientific Q221 Earnings:
Net Sales: USD3.08B (est USD2.94B)
Adj EPS: USD0.40 (est USD0.37)
Sees FY Adj EPS: USD1.58 To USD1.62 (saw: USD1.53 To USD1.60)
Sees FY Revenue: +21 To +22% (saw: +13 To +19%)
Boston Scientific Q221 Earnings:
Net Sales: USD3.08B (est USD2.94B)
Adj EPS: USD0.40 (est USD0.37)
Sees FY Adj EPS: USD1.58 To USD1.62 (saw: USD1.53 To USD1.60)
Sees FY Revenue: +21 To +22% (saw: +13 To +19%)
⚡️🇺🇸#XRX #отчетность
Xerox Releases Second-Quarter Results
Non-GAAP EPS of $0.47 beats by $0.10;
GAAP EPS of $0.46 beats by $0.20.
Revenue of $1.79B (+21.8% Y/Y) beats by $70M.
Operating cash flow totaled $214M with FCF of $198M.
Adjusted operating margin was up 280 bps on the year.
Xerox Releases Second-Quarter Results
Non-GAAP EPS of $0.47 beats by $0.10;
GAAP EPS of $0.46 beats by $0.20.
Revenue of $1.79B (+21.8% Y/Y) beats by $70M.
Operating cash flow totaled $214M with FCF of $198M.
Adjusted operating margin was up 280 bps on the year.
⚡️🇺🇸#ARCH #отчетность
Arch Coal - Q2
GAAP EPS of $1.66 beats by $0.60.
Revenue of $450.4M (+41.0% Y/Y) beats by $80.37M.
Reports adjusted EBITDA of $66.5M, vs. -$10.7M in Q2 2020.
Arch Coal - Q2
GAAP EPS of $1.66 beats by $0.60.
Revenue of $450.4M (+41.0% Y/Y) beats by $80.37M.
Reports adjusted EBITDA of $66.5M, vs. -$10.7M in Q2 2020.
⚡️💥🇺🇸#MRK
Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
⚡️🇺🇸#MSCI #отчетность
MSCI Reports Financial Results for Second Quarter and Six Months 2021
Operating revenues of $498.2 million, up 21.6%
Recurring subscription revenues up 12.3%; Asset-based fees up 54.6%
Operating margin of 51.7%; Adjusted EBITDA margin of 59.2%
Diluted EPS of $1.99, up 46.3%; Adjusted EPS of $2.45, up 38.4%
New recurring subscription sales growth of 29.3%; Organic subscription Run Rate growth of 11.3%; Retention Rate of 94.4%
#дивиденд ежеквартальный дивиденд = $1.04 (рост на 33.3%)
MSCI Reports Financial Results for Second Quarter and Six Months 2021
Operating revenues of $498.2 million, up 21.6%
Recurring subscription revenues up 12.3%; Asset-based fees up 54.6%
Operating margin of 51.7%; Adjusted EBITDA margin of 59.2%
Diluted EPS of $1.99, up 46.3%; Adjusted EPS of $2.45, up 38.4%
New recurring subscription sales growth of 29.3%; Organic subscription Run Rate growth of 11.3%; Retention Rate of 94.4%
#дивиденд ежеквартальный дивиденд = $1.04 (рост на 33.3%)
☢️🇺🇸#TSLA #BTC #крипто #трейд #отчетность
Tesla заработала $128 млн на продаже BTC в 1п 2021г - компания
TESLA INC - DURING SIX MONTHS ENDED JUNE 30, 2021, REALIZED GAINS OF $128 MILLION THROUGH SALES OF BITCOIN
——————————-
ранее: Tesla продала 10% своих BTC - подробнее
Tesla заработала $128 млн на продаже BTC в 1п 2021г - компания
TESLA INC - DURING SIX MONTHS ENDED JUNE 30, 2021, REALIZED GAINS OF $128 MILLION THROUGH SALES OF BITCOIN
——————————-
ранее: Tesla продала 10% своих BTC - подробнее
⚡️🇺🇸#RTX #отчетность
Raytheon Technologies Q221 Earnings:
Revenue: USD15.88B (est USD15.80B)
Collins, Aerospace Net Sales: USD4.55B (est USD4.59B)
Adj EPS: USD1.03 (est USD0.93)
Sees FY Adj EPS: USD3.85 To USD4.00 (saw: USD3.50 To USD3.70)
End-Backlog: USD151.8B
Raytheon Technologies Q221 Earnings:
Revenue: USD15.88B (est USD15.80B)
Collins, Aerospace Net Sales: USD4.55B (est USD4.59B)
Adj EPS: USD1.03 (est USD0.93)
Sees FY Adj EPS: USD3.85 To USD4.00 (saw: USD3.50 To USD3.70)
End-Backlog: USD151.8B
⚡️🇺🇸#JBLU #отчетность
JetBlue Announces Second Quarter 2021 Results
Non-GAAP EPS of -$0.65 beats by $0.09; GAAP EPS of $0.20 beats by $0.56.
Revenue of $1.5B (+597.7% Y/Y) beats by $60M.
#прогноз For the third quarter, we estimate our EBITDA will range between $75 and $175 million dollars
JetBlue Announces Second Quarter 2021 Results
Non-GAAP EPS of -$0.65 beats by $0.09; GAAP EPS of $0.20 beats by $0.56.
Revenue of $1.5B (+597.7% Y/Y) beats by $60M.
#прогноз For the third quarter, we estimate our EBITDA will range between $75 and $175 million dollars
⚡️🇺🇸#FISV #отчетность
Fiserv Reports Second Quarter 2021 Results
Non-GAAP EPS of $1.37 beats by $0.09;
GAAP EPS of $0.40 misses by $0.24.
Revenue of $4.05B (+16.7% Y/Y) beats by $120M.
Adjusted operating margin of 33.9% vs. a consensus of 33.7%.
#прогноз For FY2021, the company expects internal revenue growth of 10% to 12% (prior: 9-12%) and adjusted earnings per share in a range of $5.5 to $5.6 (prior: $5.35-$5.50), representing growth of 24% to 27% vs. consensus of $5.45.
Fiserv Reports Second Quarter 2021 Results
Non-GAAP EPS of $1.37 beats by $0.09;
GAAP EPS of $0.40 misses by $0.24.
Revenue of $4.05B (+16.7% Y/Y) beats by $120M.
Adjusted operating margin of 33.9% vs. a consensus of 33.7%.
#прогноз For FY2021, the company expects internal revenue growth of 10% to 12% (prior: 9-12%) and adjusted earnings per share in a range of $5.5 to $5.6 (prior: $5.35-$5.50), representing growth of 24% to 27% vs. consensus of $5.45.
⚡️🇺🇸#ADM #отчетность
Archer-Daniels-Midland Q221 Earnings:
Revenue: USD22.93B (est USD18.41B)
Ag Services, Oilseeds Operating Profit: USD570M
Nutrition Operating Profit: USD201M
Carbohydrate Solutions Operating Profit: USD383M
Adj EPS: USD1.33 (est USD1.02)
Archer-Daniels-Midland Q221 Earnings:
Revenue: USD22.93B (est USD18.41B)
Ag Services, Oilseeds Operating Profit: USD570M
Nutrition Operating Profit: USD201M
Carbohydrate Solutions Operating Profit: USD383M
Adj EPS: USD1.33 (est USD1.02)